69558-55-0 Usage
Description
Thymopentin is a kind of peptide. Peptides and polypeptides play a critical role in the immune system and are therefore predestined as a source for new approaches in immunotherapy. Thymopentin is capable of modulating the immune response. It is a fragment of the thymopoietins (TMPOs) which is a family of nuclear protein. Studies have shown that Thymopentin is capable of affecting the function of T cells and monocytes monitored by increased cGMP level and the triggering of cellular signaling. It is also capable of improve an imbalanced immune system. As an immunomodulating agent, it is clinically used in the treatment of autoimmune diseases such as atopic dermatitis, chronic lymphocytic leukemia, Sezary’s syndrome, rheumatoid arthritis and decreased immune competency. Recent study has also shown that its immuno-modulating effect can also help fight against the infection of mycobacterium tuberculosis.
Originator
Janssen (Belgium)
Uses
Different sources of media describe the Uses of 69558-55-0 differently. You can refer to the following data:
1. Thymopentin Acetate (TP-5) is a synthetic immunomodulating pentapeptide.
2. immunoregulator
Brand name
SINTOMODULINA; TIMUNOX
Clinical Use
Thymopentin is a synthetic, immunomodulating pentapeptide, representing the
active fragment of the thymus hormone, thymopoietin. Thymopentin induces
phenotypic differentiation and maturation of T-cells. It appears of value in the
treatment of primary immune deficiency, rheumatoid arthritis, atopic dermatitis,
sarcoidosis and a variety of other diseases with manifestations of disturbed
immune balance.
References
Zhang, Yan, et al. "Novel thymopentin release systems prepared from bioresorbable PLA–PEG–PLA hydrogels." International journal of pharmaceutics 386.1 (2010): 15-22.
Gonser, S., E. Weber, and G. Folkers. "Peptides and polypeptides as modulators of the immune response: thymopentin—an example with unknown mode of action." Pharmaceutica Acta Helvetiae 73.6 (1999): 265-273.
Wang, Ying, et al. "Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity." Biomaterials 35.9 (2014): 3102-3109.
Check Digit Verification of cas no
The CAS Registry Mumber 69558-55-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,5,5 and 8 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 69558-55:
(7*6)+(6*9)+(5*5)+(4*5)+(3*8)+(2*5)+(1*5)=180
180 % 10 = 0
So 69558-55-0 is a valid CAS Registry Number.
InChI:InChI=1/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1
69558-55-0Relevant articles and documents
Solid phase synthesis of thymopoietin-(32-36) using Adpoc amino acids and its biological activity
Rampold,Lundanes,Folkers,et al.
, (1980)
-
Tetrahydro-β-carboline-3-carboxyl-thymopentin: A nano-conjugate for releasing pharmacophores to treat tumor and complications
Hu, Xi,Zhao, Ming,Wang, Yuji,Wang, Yaonan,Zhao, Shurui,Wu, Jianhui,Li, Xiangmin,Peng, Shiqi
, p. 1384 - 1397 (2016/03/05)
To improve the therapeutic efficacy of cancer patients a novel conjugate of thymopentin (TP5) and (1S,3S)-1-methyl-tetrahydro-β-carboline-3-carboxylic acid (MTC) was presented. In water and mouse plasma MTCTP5 forms the nanoparticles of 14-139 nm in diameter, the suitable size for delivery in blood circulation. In mouse plasma MTCTP5 releases MTC, while in the presence of trypsin MTCTP5 releases MTC and TP5. On mouse and rat models the MTCTP5 dose dependently slows down the tumor growth, inhibits inflammatory response and blocks thrombosis. The anti-tumor activity as well as the anti-inflammation activity and anti-thrombotic activity of MTCTP5 are 100 fold and 10 fold higher than those of MTC, respectively, which are attributed to the fact that it down-regulates the plasma levels of TNF-α and IL-8 of the treated animals. The immunology enhancing activities in vitro and in vivo of MTCTP5 are similar to those of TP5, which is attributed to the fact that MTCTP5 up-regulates the plasma levels of IL-2 and CD4 as well as down-regulates the plasma level of CD8 of the treated animals. The plasma alanine transaminase, aspartate transaminase and creatinine assays indicate that MTCTP5 therapy does not injure the liver and the kidney of the animals. The survival time of MTCTP5 treated mice is significantly longer than that of TP5 treated mice.
Solvent-free peptide synthesis assisted by microwave irradiation: Environmentally benign synthesis of bioactive peptides
Mahindra, Amit,Patel, Neha,Bagra, Nitin,Jain, Rahul
, p. 3065 - 3069 (2014/01/06)
An efficient and facile, solvent-free peptide synthesis assisted by microwave irradiation, using DIC/HONB as the coupling reagent combination is reported. Key features of this original protocol are solvent-free synthesis, very short reaction time and scal